Preliminary Recommendation for the Non-Inclusion of Eribulin in the Treatment of Soft Tissue Sarcoma in the PNF

Document link: Evidence summary on eribulin in the treatment of soft tissue sarcoma patients with previous treatment of two other chemotherapeutic agents for metastatic disease

(Proponents may submit appeals to hta@doh.gov.ph until 28 June 2022 using the prescribed form accessible via https://hta.doh.gov.ph/topic-nomination/.)

Document Preview: